{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:13:53Z","timestamp":1775582033929,"version":"3.50.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Methylenedioxymethamphetamine (MDMA) is a popular drug worldwide and use is prevalent in Aotearoa New Zealand. Although associated with some significant harms, including fatalities, MDMA is ultimately less harmful than other commonly consumed drugs. We aimed to expand the understanding of MDMA harm and harm reduction strategies from a consumer perspective so that national harm reduction efforts can be better informed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted 14 semi-structured focus group discussions including 60 people (aged 18\u201367, <jats:italic>m<\/jats:italic>e<jats:italic>dian<\/jats:italic>\u2009=\u200921) who use MDMA in the Southern region of Aotearoa New Zealand to explore their thoughts and experiences regarding MDMA associated harm and harm reduction. Reflexive thematic analysis was conducted from a critical realist perspective.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Five themes were generated; (1) Mindset and setting matters; (2) Looking after your body and mind, not overdoing it; (3) Other substances increase risk and harm; (4) Trusted friends and peers are protective; and (5) Valid information is key for healthy self-determination; and one subtheme 5.1) Drug checking is essential harm reduction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We discuss the implications for MDMA consumers and aim to inform national drug policy and the harm reduction practices of consumers and organisations, for the ultimate purpose of reducing MDMA-related harm in Aotearoa New Zealand.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-01024-8","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T07:02:07Z","timestamp":1716447727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A thematic analysis of MDMA-related harm and harm reduction experiences and knowledge in Aotearoa New Zealand"],"prefix":"10.1186","volume":"21","author":[{"given":"Jai","family":"Whelan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan D.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoff","family":"Noller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"2","key":"1024_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00007691-200404000-00009","volume":"26","author":"R de la Torre","year":"2004","unstructured":"de la Torre R, Farr\u00e9 M, Roset PN, Pizarro N, Abanades S, Segura M, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and Disposition. Ther Drug Monit. 2004;26(2):137\u201344.","journal-title":"Ther Drug Monit"},{"issue":"13","key":"1024_CR2","first-page":"1843","volume":"162","author":"E Weir","year":"2000","unstructured":"Weir E. Raves: a review of the culture, the drugs and the prevention of harm. Can Med Assoc J. 2000;162(13):1843\u20138.","journal-title":"Can Med Assoc J"},{"issue":"9\u201310","key":"1024_CR3","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1081\/JA-200066822","volume":"40","author":"TFM ter Bogt","year":"2005","unstructured":"ter Bogt TFM, Engels RC. Partying hard: party style, motives for and effects of MDMA use at rave parties. Subst Use Misuse. 2005;40(9\u201310):1479\u2013502.","journal-title":"Subst Use Misuse"},{"key":"1024_CR4","doi-asserted-by":"publisher","first-page":"107494","DOI":"10.1016\/j.addbeh.2022.107494","volume":"136","author":"JE Sottile","year":"2023","unstructured":"Sottile JE, Macia KS, Wickham RE, Haug NA. Development and initial validation of an MDMA\/Ecstasy motives assessment. Addict Behav. 2023;136:107494.","journal-title":"Addict Behav"},{"issue":"2","key":"1024_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.cell.2016.06.045","volume":"166","author":"BD Heifets","year":"2016","unstructured":"Heifets BD, Malenka RC. MDMA as a probe and treatment for Social behaviors. Cell. 2016;166(2):269\u201372.","journal-title":"Cell"},{"issue":"6","key":"1024_CR6","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025\u201333.","journal-title":"Nat Med"},{"issue":"10","key":"1024_CR7","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"JM Mitchell","year":"2023","unstructured":"Mitchell JM, Ot\u2019alora GM, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29(10):2473\u201380.","journal-title":"Nat Med"},{"issue":"7","key":"1024_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1177\/0269881119841569","volume":"33","author":"Y Bonomo","year":"2019","unstructured":"Bonomo Y, Norman A, Biondo S, Bruno R, Daglish M, Dawe S, et al. The Australian drug harms ranking study. J Psychopharmacol. 2019;33(7):759\u201368.","journal-title":"J Psychopharmacol"},{"issue":"9","key":"1024_CR9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1177\/02698811231182012","volume":"37","author":"R Crossin","year":"2023","unstructured":"Crossin R, Cleland L, Wilkins C, Rychert M, Adamson S, Potiki T, et al. The New Zealand drug harms ranking study: a multi-criteria decision analysis. J Psychopharmacol. 2023;37(9):891\u2013903.","journal-title":"J Psychopharmacol"},{"issue":"9752","key":"1024_CR10","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","volume":"376","author":"DJ Nutt","year":"2010","unstructured":"Nutt DJ, King LA, Phillips LD. Independent Scientific Committee on D. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376(9752):1558\u201365.","journal-title":"Lancet"},{"issue":"6","key":"1024_CR11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/0269881115581980","volume":"29","author":"J van Amsterdam","year":"2015","unstructured":"van Amsterdam J, Nutt D, Phillips L, van den Brink W. European rating of drug harms. J Psychopharmacol. 2015;29(6):655\u201360.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"1024_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/02791072.2002.10399949","volume":"34","author":"MJ Baggott","year":"2002","unstructured":"Baggott MJ. Preventing problems in Ecstasy users: reduce use to reduce harm. J Psychoactive Drugs. 2002;34(2):145\u201362.","journal-title":"J Psychoactive Drugs"},{"issue":"11","key":"1024_CR13","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1111\/add.15493","volume":"116","author":"A Roxburgh","year":"2021","unstructured":"Roxburgh A, Sam B, Kriikku P, Mounteney J, Castanera A, Dias M, et al. Trends in MDMA-related mortality across four countries. Addiction. 2021;116(11):3094\u2013103.","journal-title":"Addiction"},{"issue":"4","key":"1024_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/14659891.2018.1436607","volume":"23","author":"KK Rigg","year":"2018","unstructured":"Rigg KK, Sharp A. Deaths related to MDMA (ecstasy\/molly): prevalence, root causes, and harm reduction interventions. J Subst Use. 2018;23(4):345\u201352.","journal-title":"J Subst Use"},{"issue":"7","key":"1024_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/hup.529","volume":"18","author":"SL Verheyden","year":"2003","unstructured":"Verheyden SL, Henry JA, Curran HV. Acute, sub-acute and long-term subjective consequences of \u2018ecstasy\u2019 (MDMA) consumption in 430 regular users. Hum Psychopharmacology: Clin Experimental. 2003;18(7):507\u201317.","journal-title":"Hum Psychopharmacology: Clin Experimental"},{"issue":"4","key":"1024_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hup.2318","volume":"28","author":"AC Parrott","year":"2013","unstructured":"Parrott AC. Human psychobiology of MDMA or \u2018Ecstasy\u2019: an overview of 25 years of empirical research. Hum Psychopharmacology: Clin Experimental. 2013;28(4):289\u2013307.","journal-title":"Hum Psychopharmacology: Clin Experimental"},{"issue":"1","key":"1024_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2009.09.009","volume":"107","author":"L Degenhardt","year":"2010","unstructured":"Degenhardt L, Bruno R, Topp L. Is ecstasy a drug of dependence? Drug Alcohol Depend. 2010;107(1):1\u201310.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1024_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.drugpo.2014.07.004","volume":"26","author":"H Uosukainen","year":"2015","unstructured":"Uosukainen H, Tacke U, Winstock AR. Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users. Int J Drug Policy. 2015;26(1):78\u201383.","journal-title":"Int J Drug Policy"},{"key":"1024_CR19","volume-title":"The Cathinone Hydra: increased cathinone and caffeine adulteration in the English MDMA market after Brexit and COVID-19 lockdowns","author":"MJ Pascoe","year":"2022","unstructured":"Pascoe MJ, Radley S, Simmons HTD, Measham F. The Cathinone Hydra: increased cathinone and caffeine adulteration in the English MDMA market after Brexit and COVID-19 lockdowns. Volume 8. Policy and Law: Drug Science; 2022."},{"issue":"3","key":"1024_CR20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00213-018-5066-6","volume":"236","author":"CF Oliver","year":"2019","unstructured":"Oliver CF, Palamar JJ, Salomone A, Simmons SJ, Philogene-Khalid HL, Stokes-McCloskey N, et al. Synthetic cathinone adulteration of illegal drugs. Psychopharmacology. 2019;236(3):869\u201379.","journal-title":"Psychopharmacology"},{"key":"1024_CR21","first-page":"277","volume-title":"Drug, set, and setting: the basis for controlled intoxicant use","author":"NE Zinberg","year":"1984","unstructured":"Zinberg NE. Drug, set, and setting: the basis for controlled intoxicant use. New Haven: Yale University Press; 1984. p. 277."},{"issue":"2","key":"1024_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/02791072.2002.10399954","volume":"34","author":"K McElrath","year":"2002","unstructured":"McElrath K, McEvoy K. Negative experiences on Ecstasy: the role of drug, set and setting. J Psychoactive Drugs. 2002;34(2):199\u2013208.","journal-title":"J Psychoactive Drugs"},{"issue":"6","key":"1024_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0955-3959(99)00038-9","volume":"10","author":"D Shewan","year":"2000","unstructured":"Shewan D, Dalgarno P, Reith G. Perceived risk and risk reduction among ecstasy users: the role of drug, set, and setting. Int J Drug Policy. 2000;10(6):431\u201353.","journal-title":"Int J Drug Policy"},{"key":"1024_CR24","unstructured":"Newcombe R. The reduction of drug-related harm: a conceptual framework for theory, practice and research. 1992. pp. 1\u201314."},{"issue":"2","key":"1024_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.drugalcdep.2005.09.009","volume":"82","author":"K Allott","year":"2006","unstructured":"Allott K, Redman J. Patterns of use and harm reduction practices of ecstasy users in Australia. Drug Alcohol Depend. 2006;82(2):168\u201376.","journal-title":"Drug Alcohol Depend"},{"key":"1024_CR26","volume-title":"Specific harm reduction strategies employed by 3,4-methylenedioxymethamphetmine\/ ecstasy users in the United States and the United Kingdom","author":"AK Davis","year":"2017","unstructured":"Davis AK, Rosenberg H. Specific harm reduction strategies employed by 3,4-methylenedioxymethamphetmine\/ ecstasy users in the United States and the United Kingdom. Volume 3. Policy and Law: Drug Science; 2017."},{"issue":"1","key":"1024_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/02791072.2009.10400671","volume":"41","author":"BC Kelly","year":"2009","unstructured":"Kelly BC. Mediating MDMA-related harm: preloading and post-loading among Ecstasy-using youth. J Psychoactive Drugs. 2009;41(1):19\u201326.","journal-title":"J Psychoactive Drugs"},{"issue":"1","key":"1024_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.drugpo.2004.09.001","volume":"16","author":"I Panagopoulos","year":"2005","unstructured":"Panagopoulos I, Ricciardelli LA. Harm reduction and decision making among recreational ecstasy users. Int J Drug Policy. 2005;16(1):54\u201364.","journal-title":"Int J Drug Policy"},{"key":"1024_CR29","doi-asserted-by":"publisher","first-page":"103334","DOI":"10.1016\/j.drugpo.2021.103334","volume":"97","author":"A Peacock","year":"2021","unstructured":"Peacock A, Gibbs D, Price O, Barratt MJ, Ezard N, Sutherland R, et al. Profile and correlates of colorimetric reagent kit use among people who use ecstasy\/MDMA and other illegal stimulants in Australia. Int J Drug Policy. 2021;97:103334.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1024_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/08897077.2013.792760","volume":"35","author":"F Fern\u00e1ndez-Calder\u00f3n","year":"2014","unstructured":"Fern\u00e1ndez-Calder\u00f3n F, Lozano-Rojas \u00d3, Rojas-Tejada A, Bilbao-Acedos I, Vidal-Gin\u00e9 C, Vergara-Moragues E, et al. Harm reduction behaviors among young polysubstance users at Raves. Substance Abuse. 2014;35(1):45\u201350.","journal-title":"Substance Abuse"},{"key":"1024_CR31","doi-asserted-by":"crossref","unstructured":"Hutton F. Drug Checking at New Zealand Festivals [Final Report]. Te Herenga Waka-Victoria University of Wellington; 2020. https:\/\/openaccess.wgtn.ac.nz\/articles\/report\/Drug_Checking_at_New_Zealand_Festivals_Final_Report_\/13936346","DOI":"10.26686\/wgtn.13936346.v1"},{"key":"1024_CR32","unstructured":"KnowYourStuffNZ. This was the summer of terrible drugs: KnowYourStuffNZ; 2021 [https:\/\/knowyourstuff.nz\/2021\/07\/07\/this-was-the-summer-of-terrible-drugs\/"},{"key":"1024_CR33","unstructured":"Annual Data Explorer 2022\/23: New Zealand Health Survey [Data File] [Internet]. 2023. https:\/\/minhealthnz.shinyapps.io\/nz-health-survey-2022-23-annual-data-explorer\/"},{"key":"1024_CR34","unstructured":"Thom K. \u2018Doing Ecstasy in Christchurch\u2019. Ecstasy users\u2019 experiences in relation to drug regulation strategies in New Zealand [Masters Thesis, University of Cantebury]. 2004."},{"key":"1024_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.drugpo.2017.09.016","volume":"51","author":"J Mounteney","year":"2018","unstructured":"Mounteney J, Griffiths P, Bo A, Cunningham A, Matias J, Pirona A. Nine reasons why ecstasy is not quite what it used to be. Int J Drug Policy. 2018;51:36\u201341.","journal-title":"Int J Drug Policy"},{"key":"1024_CR36","doi-asserted-by":"crossref","unstructured":"Elsey JWB, Wuestman VAF, Fieten A. User perceptions of long-term costs and benefits of MDMA use: findings from a large online sample. Drugs: Educ Prev Policy. 2023:1\u201313.","DOI":"10.1080\/09687637.2023.2284643"},{"issue":"4","key":"1024_CR37","first-page":"329","volume":"15","author":"G Hunt","year":"2008","unstructured":"Hunt G, Evans K. The great unmentionable: exploring the pleasures and benefits of Ecstasy from the perspectives of drug users. Drugs: Educ Prev Policy. 2008;15(4):329\u201349.","journal-title":"Drugs: Educ Prev Policy"},{"issue":"1","key":"1024_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1348\/000712600161646","volume":"91","author":"A Madill","year":"2000","unstructured":"Madill A, Jordan A, Shirley C. Objectivity and reliability in qualitative analysis: Realist, contextualist and radical constructionist epistemologies. Br J Psychol. 2000;91(1):1\u201320.","journal-title":"Br J Psychol"},{"key":"1024_CR39","unstructured":"Braun V, Clarke V. Thematic analysis: a practical guide. London; Thousand Oaks, California: SAGE; 2022. xxxiv, 338 pages p."},{"issue":"2","key":"1024_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qualitative Res Psychol"},{"issue":"4","key":"1024_CR41","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/2159676X.2019.1628806","volume":"11","author":"V Braun","year":"2019","unstructured":"Braun V, Clarke V. Reflecting on reflexive thematic analysis. Qualitative Res Sport Exerc Health. 2019;11(4):589\u201397.","journal-title":"Qualitative Res Sport Exerc Health"},{"key":"1024_CR42","unstructured":"Winstock AR. MDMA \u2013 how you take it might be more important that you think. Global Drug Survey.2017 [https:\/\/www.globaldrugsurvey.com\/mdma-how-you-take-it-might-be-more-important-that-you-think\/"},{"key":"1024_CR43","doi-asserted-by":"publisher","first-page":"824288","DOI":"10.3389\/fpsyt.2021.824288","volume":"12","author":"T Makunts","year":"2021","unstructured":"Makunts T, Jerome L, Abagyan R, de Boer A. Reported cases of serotonin syndrome in MDMA users in FAERS Database. Front Psychiatry. 2021;12:824288.","journal-title":"Front Psychiatry"},{"issue":"4","key":"1024_CR44","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0091-3057(01)00711-0","volume":"71","author":"A Parrott","year":"2002","unstructured":"Parrott A. Recreational Ecstasy\/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav. 2002;71(4):837\u201344.","journal-title":"Pharmacol Biochem Behav"},{"issue":"8","key":"1024_CR45","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/00048670701449237","volume":"41","author":"E Silins","year":"2007","unstructured":"Silins E, Copeland J, Dillon P. Qualitative review of Serotonin Syndrome, Ecstasy (MDMA) and the use of other Serotonergic substances: Hierarchy of Risk. Australian New Z J Psychiatry. 2007;41(8):649\u201355.","journal-title":"Australian New Z J Psychiatry"},{"key":"1024_CR46","unstructured":"Aldridge J, Measham F, Williams L. Illegal leisure revisited: changing patterns of alcohol and drug use in adolescents and young adults. Routledge; 2011."},{"key":"1024_CR47","unstructured":"World Health Organization. WHO Expert Committee on Drug Dependence: forty-fourth report. Geneva: World Health Organization. 2022. https:\/\/iris.who.int\/bitstream\/handle\/10665\/352462\/9789240042834-eng.pdf?sequence=1"},{"issue":"8","key":"1024_CR48","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/j.1360-0443.1992.tb02003.x","volume":"87","author":"N Solowij","year":"1992","unstructured":"Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of \u2018Ecstasy\u2019 users and their experiences with the drug. Br J Addict. 1992;87(8):1161\u201372.","journal-title":"Br J Addict"},{"issue":"10","key":"1024_CR49","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1592\/phco.23.12.1238.32704","volume":"23","author":"RA Murray","year":"2003","unstructured":"Murray RA, Doering PL, Boothby LA, Merves ML, McCusker RR, Chronister CW, et al. Putting an Ecstasy Test Kit to the test: harm reduction or harm induction? Pharmacotherapy. 2003;23(10):1238\u201344.","journal-title":"Pharmacotherapy"},{"issue":"8","key":"1024_CR50","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1046\/j.1360-0443.2001.96811397.x","volume":"96","author":"AR Winstock","year":"2001","unstructured":"Winstock AR, Wolff K, Ramsey J. Ecstasy pill testing: harm minimization gone too far? Addiction. 2001;96(8):1139\u201348.","journal-title":"Addiction"},{"issue":"1","key":"1024_CR51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/13676260600983668","volume":"10","author":"GP Hunt","year":"2007","unstructured":"Hunt GP, Evans K, Kares F. Drug use and meanings of risk and pleasure. J Youth Stud. 2007;10(1):73\u201396.","journal-title":"J Youth Stud"},{"key":"1024_CR52","first-page":"239","volume-title":"Pursuit of ecstasy: the MDMA experience","author":"J Beck","year":"1994","unstructured":"Beck J, Rosenbaum M. Pursuit of ecstasy: the MDMA experience. Albany: State University of New York; 1994. p. 239."},{"issue":"1","key":"1024_CR53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1375\/acri.43.1.91","volume":"43","author":"F Hutton","year":"2010","unstructured":"Hutton F, Australian. New Z J Criminol. 2010;43(1):91\u2013111.","journal-title":"New Z J Criminol"},{"issue":"3","key":"1024_CR54","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/0269881106063270","volume":"20","author":"PN Murphy","year":"2006","unstructured":"Murphy PN, Wareing M, Fisk JE. Users\u2019 perceptions of the risks and effects of taking ecstasy (MDMA): a questionnaire study. J Psychopharmacol. 2006;20(3):447\u201355.","journal-title":"J Psychopharmacol"},{"key":"1024_CR55","unstructured":"T\u016bturu. What\u2019s happening with AoD education in New Zealand schools? T\u016bturu. 2023 [https:\/\/tuturu.org.nz\/stories\/whats-happening-with-aod-education-in-new-zealand-schools"},{"issue":"6","key":"1024_CR56","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1007\/s12640-021-00416-z","volume":"39","author":"J van Amsterdam","year":"2021","unstructured":"van Amsterdam J, Brunt TM, Pierce M, van den Brink W. Hard boiled: Alcohol Use as a risk factor for MDMA-Induced Hyperthermia: a systematic review. Neurotox Res. 2021;39(6):2120\u201333.","journal-title":"Neurotox Res"},{"issue":"5","key":"1024_CR57","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.drugpo.2007.07.003","volume":"19","author":"C Duff","year":"2008","unstructured":"Duff C. The pleasure in context. Int J Drug Policy. 2008;19(5):384\u201392.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1024_CR58","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.drugpo.2008.10.003","volume":"20","author":"T Rhodes","year":"2009","unstructured":"Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. 2009;20(3):193\u2013201.","journal-title":"Int J Drug Policy"},{"issue":"1336","key":"1024_CR59","first-page":"85","volume":"124","author":"N Wilson","year":"2011","unstructured":"Wilson N, Gunasekara FI, Thomson G. The benefits and harms of alcohol use in New Zealand: what politicians might consider. N Z Med J. 2011;124(1336):85\u20139.","journal-title":"N Z Med J"},{"key":"1024_CR60","doi-asserted-by":"crossref","unstructured":"Span C, Farah B, Ivet\u00ecc N, Stronach O. A scoping review of Australian literature on people who use MDMA and their harm reduction practices. Contemporary Drug Problems; 2023.","DOI":"10.1177\/00914509231214342"},{"key":"1024_CR61","unstructured":"Duff C, Johnston J, Moore D, Goren N. Dropping, connecting, playing and partying: Exploring the social and cultural contexts of ecstasy and related drug use in Victoria. Melbourne: Premier\u2019s Drug Prevention Council; 2007. https:\/\/vgls.sdp.sirsidynix.net.au\/client\/search\/asset\/1161131"},{"issue":"3","key":"1024_CR62","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2307\/2948371","volume":"8","author":"HS Becker","year":"1967","unstructured":"Becker HS, History. Culture and subjective experience: an exploration of the Social bases of Drug-Induced experiences. J Health Soc Behav. 1967;8(3):163\u201376.","journal-title":"J Health Soc Behav"},{"issue":"3","key":"1024_CR63","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/0091450916663248","volume":"43","author":"I Van Schipstal","year":"2016","unstructured":"Van Schipstal I, Mishra S, Berning M, Murray H. Harm reduction from below: on sharing and caring in Drug Use. Contemp Drug Probl. 2016;43(3):199\u2013215.","journal-title":"Contemp Drug Probl"},{"issue":"5","key":"1024_CR64","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.drugpo.2007.09.003","volume":"19","author":"C Jacinto","year":"2008","unstructured":"Jacinto C, Duterte M, Sales P, Murphy S. Maximising the highs and minimising the lows: harm reduction guidance within ecstasy distribution networks. Int J Drug Policy. 2008;19(5):393\u2013400.","journal-title":"Int J Drug Policy"},{"key":"1024_CR65","doi-asserted-by":"publisher","first-page":"102845","DOI":"10.1016\/j.drugpo.2020.102845","volume":"87","author":"A Betsos","year":"2021","unstructured":"Betsos A, Valleriani J, Boyd J, Bardwell G, Kerr T, McNeil R. I couldn\u2019t live with killing one of my friends or anybody: a rapid ethnographic study of drug sellers\u2019 use of drug checking. Int J Drug Policy. 2021;87:102845.","journal-title":"Int J Drug Policy"},{"key":"1024_CR66","doi-asserted-by":"publisher","first-page":"103819","DOI":"10.1016\/j.drugpo.2022.103819","volume":"108","author":"R van der Sanden","year":"2022","unstructured":"van der Sanden R, Wilkins C, Rychert M, Barratt MJ. Choice\u2019 of social media platform or encrypted messaging app to buy and sell illegal drugs. Int J Drug Policy. 2022;108:103819.","journal-title":"Int J Drug Policy"},{"key":"1024_CR67","volume-title":"Illegal leisure: the normalisation of adolescent","author":"H Parker","year":"1998","unstructured":"Parker H, Aldridge J, Measham F. Illegal leisure: the normalisation of adolescent. Recreational Drug Use: Routledge; 1998."},{"issue":"2","key":"1024_CR68","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.drugalcdep.2004.08.014","volume":"77","author":"A Gamma","year":"2005","unstructured":"Gamma A, Jerome L, Liechti ME, Sumnall HR. Is ecstasy perceived to be safe? A critical survey. Drug Alcohol Depend. 2005;77(2):185\u201393.","journal-title":"Drug Alcohol Depend"},{"key":"1024_CR69","unstructured":"Gascoigne M, Dillon P, Copeland J. Sources of ecstasy information: their use and perceived credibility. 2004. Contract No.: Technical Report No. 202. https:\/\/ndarc.med.unsw.edu.au\/sites\/default\/files\/ndarc\/resources\/TR.202.pdf"},{"issue":"1","key":"1024_CR70","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.drugalcdep.2003.11.009","volume":"74","author":"RS Falck","year":"2004","unstructured":"Falck RS, Carlson RG, Wang J, Siegal HA. Sources of information about MDMA (3,4-methylenedioxymethamphetamine): perceived accuracy, importance, and implications for prevention among young adult users. Drug Alcohol Depend. 2004;74(1):45\u201354.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1024_CR71","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1477-7517-11-25","volume":"11","author":"C Soussan","year":"2014","unstructured":"Soussan C, Kjellgren A. Harm reduction and knowledge exchange\u2014a qualitative analysis of drug-related internet discussion forums. Harm Reduct J. 2014;11(1):25.","journal-title":"Harm Reduct J"},{"issue":"3","key":"1024_CR72","first-page":"195","volume":"20","author":"MJ Barratt","year":"2013","unstructured":"Barratt MJ, Lenton S, Allen M. Internet content regulation, public drug websites and the growth in hidden internet services. Drugs: Educ Prev Policy. 2013;20(3):195\u2013202.","journal-title":"Drugs: Educ Prev Policy"},{"issue":"3","key":"1024_CR73","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/asi.20722","volume":"59","author":"K Kelton","year":"2008","unstructured":"Kelton K, Fleischmann KR, Wallace WA. Trust in digital information. J Am Soc Inform Sci Technol. 2008;59(3):363\u201374.","journal-title":"J Am Soc Inform Sci Technol"},{"key":"1024_CR74","doi-asserted-by":"crossref","unstructured":"Maghsoudi N, Tanguay J, Scarfone K, Rammohan I, Ziegler C, Werb D et al. The Implementation of Drug Checking Services for People Who Use Drugs: A Systematic Review. Addiction. 2022:532\u2009\u2013\u200944.","DOI":"10.32388\/TXE86U.2"},{"issue":"1","key":"1024_CR75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12954-024-00979-y","volume":"21","author":"J Whelan","year":"2024","unstructured":"Whelan J, Noller G, Ward RD. Harm reduction behaviours and harm experiences of people who use 3,4-methylenedioxymethamphetamine (MDMA) in Aotearoa New Zealand. Harm Reduct J. 2024;21(1):67.","journal-title":"Harm Reduct J"},{"key":"1024_CR76","unstructured":"KnowYourStuffNZ. 2 years of legal drug checking today! KnowYourStuffNZ. 2023, November 25 [https:\/\/knowyourstuff.nz\/2023\/11\/25\/2-years-of-legal-drug-checking-today\/"},{"key":"1024_CR77","unstructured":"Ministry of Health. Drug checking: Ministry of Health; [https:\/\/www.health.govt.nz\/our-work\/regulation-health-and-disability-system\/drug-checking#:~:text=Permanent%20drug%20checking%20licensing%20under,drugs%20for%20drug%20checking%20purposes"},{"key":"1024_CR78","unstructured":"KnowYourStuffNZ. Pill Library: KnowYourStuffNZ; [https:\/\/knowyourstuff.nz\/pill-library\/"},{"key":"1024_CR79","unstructured":"New Zealand Police. Wastewater Drug Testing in New Zealand: National Overview. Quarter Four: October - December 2021. New Zealand Police. 2022. https:\/\/www.police.govt.nz\/sites\/default\/files\/publications\/wastewater-results-quarter-4-2021.pdf"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01024-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01024-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01024-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T08:08:56Z","timestamp":1716451736000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01024-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1024"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01024-8","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was given by the Human Ethics Committee of the University of Otago (Ref: 21\/017).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}